Related Experiment Videos
Future therapeutics for osteoarthritis
Johanne Martel-Pelletier1, Lukas M Wildi, Jean-Pierre Pelletier
1Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada. jm@martelpelletier.ca
Abstract:
Osteoarthritis (OA) is a disease of the joints that affects several million individuals worldwide. This disease, which involves mainly the diarthrodial joints, is chronic and develops slowly over decades, making it very difficult to precisely identify the different etiological and risk factors that influence its onset. At present, most therapies for OA are symptomatic. This review will focus on new OA therapeutics in development that are directed toward pain relief as well as others with the potential to reduce or stop the progression of the disease (DMOADs). This article is part of a Special Issue entitled "Osteoarthritis".
Insights
New osteoarthritis (OA) therapeutics are emerging to manage joint pain and potentially halt disease progression. This review explores promising treatments in development for osteoarthritis.
Area of Science:
- Rheumatology
- Orthopedics
- Pharmacology
Background:
- Osteoarthritis (OA) is a prevalent, chronic joint disease affecting millions globally.
- Its slow, decades-long development complicates identifying etiological and risk factors.
- Current OA treatments primarily offer symptomatic relief.
Purpose of the Study:
- To review novel therapeutics for osteoarthritis (OA) currently in development.
- To highlight treatments targeting pain relief.
- To discuss disease-modifying osteoarthritis drugs (DMOADs) with potential to halt OA progression.
Main Methods:
- Literature review of ongoing OA therapeutic research.
- Focus on preclinical and clinical studies of new OA drugs.
- Analysis of agents targeting pain and disease modification.
Main Results:
- Several novel drug candidates are under investigation for OA.
- Emerging treatments aim to address both pain and underlying disease mechanisms.
- Disease-modifying osteoarthritis drugs (DMOADs) represent a significant area of research.
Conclusions:
- The pipeline for OA therapeutics is expanding beyond symptomatic treatments.
- Future OA management may include therapies that modify disease progression.
- Continued research is crucial for developing effective OA treatments.